TD Cowen lowered the firm’s price target on Legend Biotech to $67 from $71 and keeps a Buy rating on the shares. The firm anticipates sales will meet our/consensus estimates. Cowen has high conviction in the ramp in H2 but are trimming estimates as Q3 will likely show nice growth and Q4 growthquarter-over-quarter will likely be moderate.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Legend Biotech up 10% after report claims company received takeover interest
- Legend Biotech said to receive takeover approach, Street Insider reports
- Legend Biotech to Host Investor Conference Call on Second Quarter 2024 Results
- 3 Best Stocks to Buy Now, 7/4/2024, According to Top Analysts
- Legend Biotech’s CARVYKTI® Triumphs in Phase 3 Trial